BR112022010280A2 - Terapia de combinação de ciclosserina e lítio para o tratamento da depressão - Google Patents

Terapia de combinação de ciclosserina e lítio para o tratamento da depressão

Info

Publication number
BR112022010280A2
BR112022010280A2 BR112022010280A BR112022010280A BR112022010280A2 BR 112022010280 A2 BR112022010280 A2 BR 112022010280A2 BR 112022010280 A BR112022010280 A BR 112022010280A BR 112022010280 A BR112022010280 A BR 112022010280A BR 112022010280 A2 BR112022010280 A2 BR 112022010280A2
Authority
BR
Brazil
Prior art keywords
depression
combination therapy
treatment
lithium
cyclosserine
Prior art date
Application number
BR112022010280A
Other languages
English (en)
Inventor
Lee Sukchan
Ha Chi Yong
Cheol Jang Dong
Kwon Gibeom
Original Assignee
Neurorive Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurorive Inc filed Critical Neurorive Inc
Publication of BR112022010280A2 publication Critical patent/BR112022010280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1604—Lithium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

TERAPIA DE COMBINAÇÃO DE CICLOSSERINA E LÍTIO PARA O TRATAMENTO DA DEPRESSÃO. A presente invenção se refere a uma terapia de combinação de ciclosserina e lítio para a prevenção ou o tratamento da depressão. A administração combinada de ciclosserina e lítio de acordo com a presente invenção tem um efeito notavelmente excelente de prevenção ou tratamento da depressão em comparação com cada administração única, sendo assim utilizada eficazmente como uma terapia de combinação para antidepressivos.
BR112022010280A 2019-11-27 2020-11-27 Terapia de combinação de ciclosserina e lítio para o tratamento da depressão BR112022010280A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190154218 2019-11-27
PCT/KR2020/017101 WO2021107690A1 (en) 2019-11-27 2020-11-27 Combination therapy of cycloserine and lithium for the treatment of depression

Publications (1)

Publication Number Publication Date
BR112022010280A2 true BR112022010280A2 (pt) 2022-08-16

Family

ID=76129568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010280A BR112022010280A2 (pt) 2019-11-27 2020-11-27 Terapia de combinação de ciclosserina e lítio para o tratamento da depressão

Country Status (9)

Country Link
US (1) US20220387481A1 (pt)
EP (1) EP4065109A4 (pt)
JP (1) JP2023501131A (pt)
KR (1) KR102287477B1 (pt)
AU (1) AU2020391291B2 (pt)
BR (1) BR112022010280A2 (pt)
CA (1) CA3154457C (pt)
MX (1) MX2022006342A (pt)
WO (1) WO2021107690A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2010099217A1 (en) * 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2012104852A1 (en) * 2011-01-31 2012-08-09 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder

Also Published As

Publication number Publication date
WO2021107690A1 (en) 2021-06-03
AU2020391291B2 (en) 2024-04-18
US20220387481A1 (en) 2022-12-08
KR20210065892A (ko) 2021-06-04
MX2022006342A (es) 2022-08-11
EP4065109A4 (en) 2023-09-13
CA3154457A1 (en) 2021-06-03
EP4065109A1 (en) 2022-10-05
JP2023501131A (ja) 2023-01-18
CA3154457C (en) 2024-06-25
KR102287477B1 (ko) 2021-08-09
CN114786668A (zh) 2022-07-22
AU2020391291A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
PH12017502103A1 (en) Methods and kits for treating depression
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
NZ757081A (en) Somatostatin modulators and uses thereof
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.
BR112022006016A2 (pt) Métodos e materiais para tratar neurotoxicidade
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
MX2018007048A (es) Composiciones para el cuidado bucal que comprenden al menos un copolimero de fosfato / acrilato y al menos un ingrediente activo cationico.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112016017478A2 (pt) novos tratamentos
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof